Pune-based Emcure Pharmaceuticals has announced its consolidated financial results for the quarter ending June 30, 2025, showcasing solid growth across key business segments. The company reported a 16% year-on-year increase in revenue and a notable 41% jump in profit after tax, reflecting strong operational momentum.
The international segment delivered a 22% increase, driven by positive performance across all regions. The Rest of the World operations grew by 42%, while the Canadian business expanded 16.4%, supported by successful new product launches and increased market share. In Europe, early traction from recent product rollouts contributed to a 12.8% growth.
On the domestic front, revenue rose 9.4%, supported by steady performance across core therapeutic areas and the introduction of new initiatives in dermatology and over-the-counter products. The quarter also marked a strategic milestone, as Emcure broadened its partnership with Sanofi to include marketing and distribution of Sanofi’s oral anti-diabetes treatments in addition to cardiovascular offerings.
Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals, commented on the quarterly performance: “All our business segments delivered strong results. Our focus on expanding the portfolio through both internal R&D and external collaborations is bearing fruit. The enhanced collaboration with Sanofi will further boost our presence in the fast-growing metabolic segment. We are committed to operational efficiency and margin expansion as we continue to grow.”
Emcure Pharmaceuticals Ltd, founded in 1981 and headquartered in Pune, ranks among India’s top pharmaceutical companies by domestic sales (12th as of MAT June 2024). With a global footprint across more than 70 countries, including significant presence in Europe and Canada, Emcure focuses on developing and marketing a diverse portfolio of innovative, high-quality pharmaceutical products across major therapeutic segments.
